Opinion|Videos|February 10, 2025
Navigating New Treatment Options for Pediatric Atopic Dermatitis Management
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Vaccine schedule overhaul raises concerns about delayed protection and access, says Ravi Jhaveri, MD
2
Rethinking screen time for back to school
3
Building trust may be key to vaccine conversations with hesitant families
4
Eczema, delayed allergen introduction, and early antibiotics top list of childhood food allergy risk factors
5